Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Action Pharma A/s

Michael Szardenings

Ingo Grunwald

Jarl Wikberg

Klaus Rischka

Ruta Muceniece

Ilze Mutule

Felikss Mutulis

Katharina Richter

Nicolas Delaroque

Annika Eisenschmidt

Andreas Brinkmann

Regina Corrales Urena Yendry

A library of replicating entities, each entity comprises a recombinant vector comprising a randomized nucleic acid sequence, having the reading frame structure [NXX][CorAA] [NXX][NZZ], or [NZZ][NXX][CorAA] [NXX]. Each NXX is independently a codon encoding for any amino acid except cysteine, CorAA is a codon encoding for cysteine or at least one other amino acid, each NZZ is independently a codon encoding for any amino acid, and n is an integer from 0 to 40, m is an integer from 1 to 20, o is an integer from 1 to 40, and at least 20 percent of CorAA encode for cysteine. The invention further relates to a set of recombinant vectors and to a set of randomized oligonucleotides, each oligonucleotide having said structure, as well as to a method for generating a library of replicating entities and to a method for identifying an amino acid polymer.

Phage display library

The invention relates to a method for activating a surface by increasing the hydrophilicity and/or for binding target structures, particularly selected from the group consisting of proteins, cellular proteins, proteins, cells, carbohydrates, peptides and amino acids. It also relates to the use of an oxidoreductase for activating a surface for the mentioned bonds and to corresponding activated surfaces.

Method for activating a surface by increasing the hydrophilicity and/or for  binding target structures

Method for marking a target structure, comprising the following steps:

Method for marking or immobilising a target structure

The invention relates to methods of treatment comprising administering a compound of the general formula (1): to a patient or a healthy individual.

Melanocortin 1 receptor selective compounds

A compound of general formula (1) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are H or methyl, R13, R14, R15 and R16 are H or alkyl, wherein L1 and L2 are linkers selected from single bond, methyl, ethyl, wherein R19, R20 and R21 are H or &#x2014;CHX, NT is selected from H, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group, CT is selected from hydrogen, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group shows high selectivity and high affinity for MC1-receptors in combination with effective stimulation or inhibiton of cAMP formation in MC1-receptor expressing cells but low affinity for other subtypes of MC-receptors and may be used to treat a wide range of inflammatory conditions. Also disclosed is a DNA molecule and a corresponding vector encoding the compound, a fusion protein comprising a copy of it, a vector comprising DNA encoding the fusion protein, and a pharmaceutical composition comprising the compound.

Growing community of inventors

Wolfenbüttel, Germany

Michael Szardenings